Journal article

Whole-genome sequencing analysis of clozapine-induced myocarditis

A Narang, P Lacaze, KJ Ronaldson, JJ McNeil, M Jayaram, N Thomas, R Sellmer, DN Crockford, R Stowe, SC Greenway, C Pantelis, CA Bousman

Pharmacogenomics Journal | SPRINGERNATURE | Published : 2022

Abstract

One of the concerns limiting the use of clozapine in schizophrenia treatment is the risk of rare but potentially fatal myocarditis. Our previous genome-wide association study and human leucocyte antigen analyses identified putative loci associated with clozapine-induced myocarditis. However, the contribution of DNA variation in cytochrome P450 genes, copy number variants and rare deleterious variants have not been investigated. We explored these unexplored classes of DNA variation using whole-genome sequencing data from 25 cases with clozapine-induced myocarditis and 25 demographically-matched clozapine-tolerant control subjects. We identified 15 genes based on rare variant gene-burden analy..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

The work was supported in part by the University of Calgary Cumming School of Medicine, Alberta Children's Hospital Research Institute, and University of Melbourne Establishment Grant. P.L is supported by a National Heart Foundation Future Leader Fellowship (102604). JMCN is supported by an NHMRC Leadership award (IG1173690). CP was supported by a National Health and Medical Research Council (NHMRC) L3 Investigator Grant (1196508) and NHMRC Program Grant (ID: 566529). Access to high performance computing was provided by The Centre for Health Genomics and Informatics (CHGI) at University of Calgary.